SAG and metabolic dysfunction-associated steatotic liver disease: Thus, targeting the UBE2F-SAG axis may have therapeutic implications for the treatment of non-alcoholic fatty liver disease and liver cancer with activated mTORC1 signal as a result of PTEN loss.